摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-carboxamidine-4-N-methylamino-6-methylthio-1-(β-D-ribofuranosyl)pyrazolo<3,4-d>pyrimidine | 125284-50-6

中文名称
——
中文别名
——
英文名称
3-carboxamidine-4-N-methylamino-6-methylthio-1-(β-D-ribofuranosyl)pyrazolo<3,4-d>pyrimidine
英文别名
3-carboxamidine-4-methylamino-6-methylthio-1-(β-D-ribofuranosyl)-1H-pyrazolo<3.4-d>pyrimidine;1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-(methylamino)-6-methylsulfanylpyrazolo[3,4-d]pyrimidine-3-carboximidamide
3-carboxamidine-4-N-methylamino-6-methylthio-1-(β-D-ribofuranosyl)pyrazolo<3,4-d>pyrimidine化学式
CAS
125284-50-6
化学式
C13H19N7O4S
mdl
——
分子量
369.404
InChiKey
QUDSPLBHXMGOSA-BFAGERDPSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -1
  • 重原子数:
    25
  • 可旋转键数:
    5
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.54
  • 拓扑面积:
    201
  • 氢给体数:
    6
  • 氢受体数:
    10

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    8-amino-6-N-methyl-4-(methylthio)-2-β-D-ribofuranosyl-1,2,3,5,6,7-hexaazaacenaphthylene碳酸甲丙酯 作用下, 反应 18.0h, 以31%的产率得到3-carboxamidine-4-N-methylamino-6-methylthio-1-(β-D-ribofuranosyl)pyrazolo<3,4-d>pyrimidine
    参考文献:
    名称:
    8-氨基-4-甲硫基-6-甲基-2-(β-D-呋喃呋喃糖基)-2,6-二氢-1,2,3,5,6,7-六氮杂ena烯的合成及不寻常的还原性开环1,2,3,5,6,7-六氮杂ena烯环体系的合成
    摘要:
    由3-氰基-4合成三环核苷8-氨基-4-甲硫基-6-甲基-2-(β-D-呋喃呋喃糖基)-1,2,3,5,6,7-六氮杂ena烯(3), 6-双(甲硫基)-1-(β-D-呋喃呋喃糖基)吡唑并[3,4- d ]嘧啶(1)。尝试合成8-氨基-6-甲基-2-(β-D-呋喃呋喃糖基)-1 H -2,6-二氢-1,2,3,5,6,7-六氮杂ena烯(5)([aza 6-氨基-4-甲基-8-(β-d-D-呋喃核糖基)-1,3,4,5,8-pentaazaacenaphthylene(TCN)],这是一种有效的抗肿瘤剂),由治疗的模拟3与阮内镍没有提供所需的TCN的氮杂类似物。取而代之的是,确定了3的哒嗪部分的还原性切割。产生4-甲基氨基-6-甲硫基-1-(β-D-呋喃呋喃糖基)-1 H-吡唑并[3,4- d ]嘧啶-3-甲am(6)。假设溶解度在还原步骤中的问题,对异亚丙基衍生物3,8-氨基-6-甲基-4-甲硫基-2-(2
    DOI:
    10.1002/jhet.5570280101
点击查看最新优质反应信息

文献信息

  • An unusual reductive ring-opening of the 1,2,3,5,6,7-hexaazaacenaphthylene ring system
    作者:Andrew M. Kawasaki、Leroy B. Townsend
    DOI:10.1016/s0040-4039(00)99223-2
    日期:1989.1
    Studies on an unexpected reaction involving a reductive cleavage of the pyridazine moiety of a tricyclic heterocycle are described. Structure assignments for the products obtained from the reductive cleavage were made using physicochemical methods.
    描述了对涉及三环杂环的哒嗪部分的还原性切割的意外反应的研究。由还原裂解获得的产物的结构分配是使用物理化学方法进行的。
  • KAWASAKI, ANDREW M.;TOWNSEND, LEROY B., TETRAHEDRON LETT., 30,(1989) N5, C. 3287-3290
    作者:KAWASAKI, ANDREW M.、TOWNSEND, LEROY B.
    DOI:——
    日期:——
  • KAWASAKI, ANDREW M.;TOWNSEND, LEROY B., J. HETEROCYCL. CHEM., 28,(1991) N, C. 1-5
    作者:KAWASAKI, ANDREW M.、TOWNSEND, LEROY B.
    DOI:——
    日期:——
  • Synthesis of 8-amino-4-methylthio-6-methyl-2-(β-D-ribofuranosyl)-2,6-dihydro-1,2,3,5,6,7-hexaazaacenaphthylene and an unusual reductive ring-opening of the 1,2,3,5,6,7-hexaazaacenaphthylene ring system
    作者:Andrew M. Kawasaki、Leroy B. Townsend
    DOI:10.1002/jhet.5570280101
    日期:1991.1
    The tricyclic nucleoside 8-amino-4-methylthio-6-methyl-2-(β-D-ribofuranosyl)-1,2,3,5,6,7-hexaazaacenaphthylene (3) was synthesized from 3-cyano-4,6-bis(methylthio)-1-(β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine (1). Attempts to synthesize 8-amino-6-methyl-2-(β-D-ribofuranosyl)-1H-2,6-dihydro-1,2,3,5,6,7-hexaazaacenaphthylene (5) ([an aza analog of 6-amino-4-methyl-8-(β-D-ribofuranosyl)-1,3,4,5,8-p
    由3-氰基-4合成三环核苷8-氨基-4-甲硫基-6-甲基-2-(β-D-呋喃呋喃糖基)-1,2,3,5,6,7-六氮杂ena烯(3), 6-双(甲硫基)-1-(β-D-呋喃呋喃糖基)吡唑并[3,4- d ]嘧啶(1)。尝试合成8-氨基-6-甲基-2-(β-D-呋喃呋喃糖基)-1 H -2,6-二氢-1,2,3,5,6,7-六氮杂ena烯(5)([aza 6-氨基-4-甲基-8-(β-d-D-呋喃核糖基)-1,3,4,5,8-pentaazaacenaphthylene(TCN)],这是一种有效的抗肿瘤剂),由治疗的模拟3与阮内镍没有提供所需的TCN的氮杂类似物。取而代之的是,确定了3的哒嗪部分的还原性切割。产生4-甲基氨基-6-甲硫基-1-(β-D-呋喃呋喃糖基)-1 H-吡唑并[3,4- d ]嘧啶-3-甲am(6)。假设溶解度在还原步骤中的问题,对异亚丙基衍生物3,8-氨基-6-甲基-4-甲硫基-2-(2
查看更多

同类化合物

别嘌呤醇核糖苷 [3,4-二乙酰氧基-5-(5-甲硫基-2,4,8,9-四氮杂双环[4.3.0]壬-2,4,7,10-四烯-9-基)四氢呋喃-2-基]甲基乙酸酯 4-氨基-3-苄基-1H-吡唑并[3,4-d]嘧啶-1-β-D-呋喃核糖 1 beta-呋喃核糖基-4-(甲硫基)吡唑并(3,4-d)嘧啶 4-amino-3-bromo-6-methoxy-1-(β-D-ribofuranosyl)-1H-pyrazolo[3,4-d]pyrimidine 4-amino-3-bromo-5-methyl-1-(β-D-ribofuranosyl)-1H-pyrazolo[3,4-d]pyrimidine-6-one 8-aza-7-deaza-7-propynyladenosine 1-(β-D-ribofuranosyl)-4,6-bis(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine 1-(β-D-ribofuranosyl)-3-carboxy-4,6-dimethylmercaptopyrazolo<3,4-d>pyrimidine 4-amino-1-(α-D-arabinofuranosyl)pyrazolo<3,4-d>pyrimidine 2-(5-Amino-4-iminopyrazolo[3,4-d]pyrimidin-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol;hydrochloride 1-(β-D-ribofuranosyl)-3-thiocarbamoyl-4-amino-6-methylmercaptopyrazolo<3,4-d>pyrimidine 1-(β-D-ribofuranosyl)-4-amino-6-methylmercaptopyrazolo<3,4-d>pyrimidine-3-carboxamidine 1-(β-D-ribofuranosyl)-3-thiocarbamoyl-4,6-dimethylmercaptopyrazolo<3,4-d>pyrimidine 1-(β-D-ribofuranosyl)-3-cyano-4-(N-piperidino)-6-methylmercaptopyrazolo<3,4-d>pyrimidine 1-(β-D-ribofuranosyl)-3-cyano-4-(N-morpholino)-6-methylmercaptopyrazolo<3,4-d>pyrimidine methyl 1-(β-D-ribofuranosyl)-4,6-dimethylmercaptopyrazolo<3,4-d>pyrimidine-3-imidocarboxylate 1-(β-D-ribofuranosyl)-3-cyanomethyl-4-(N-morpholino)-6-methylmercaptopyrazolo<3,4-d>pyrimidine methyl 1-(β-D-ribofuranosyl)-4-methoxy-6-methylmercaptopyrazolo<3,4-d>pyrimidine-3-imidocarboxylate 1-(β-D-ribofuranosyl)-3-cyanomethyl-4-amino-6-methylmercaptopyrazolo<3,4-d>pyrimidine methyl 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl) tetrahydrofuran- 2-yl]-1H-pyrazolo[3,4-d]pyrimidine-3-carboximidoate 4-amino-1-(2,3,5-tri-O-benzyl-α-D-arabinofuranosyl)pyrazolo<3,4-d>pyrimidine 4-Amino-3-methoxy-1-β-D-ribofuranosylpyrazolo<3,4-d>pyrimidine 4-amino-1-β-D-ribofuranosylpyrazolo<3,4-d>pyrimidine-3-carbonitrile 4-amino-1-(β-D-ribofuranosyl)-3-[2-(methoxycarbonyl)ethenyl]-1H-pyrazolo[3,4-d]pyrimidine 1-Pentofuranosyl-1h-pyrazolo[3,4-d]pyrimidin-4-amine 4-Amino-1-pentofuranosyl-1h-pyrazolo[3,4-d]pyrimidine-3-carbonitrile 4-Amino-1-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrazolo[3,4-d]pyrimidine-3-carboximidamide Methyl 4-amino-1-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrazolo[3,4-d]pyrimidine-3-carboximidate 1H-Pyrazolo[3, 4-amino-1-beta-D-ribofuranosyl-, hydrazide, hemihydrate 2-(Hydroxymethyl)-5-[4-(methylamino)pyrazolo[3,4-d]pyrimidin-1-yl]oxolane-3,4-diol [3,4-Diacetyloxy-5-(4-chloropyrazolo[3,4-d]pyrimidin-1-yl)oxolan-2-yl]methyl acetate 1-beta-D-ribofuranosyl-4-methoxypyrazolo[3,4-d] pyrimidine 2-[4-(Dimethylamino)pyrazolo[3,4-d]pyrimidin-1-yl]-5-(hydroxymethyl)oxolane-3,4-diol 4-{[(4-Nitrophenyl)methyl]sulfanyl}-1-pentofuranosyl-1H-pyrazolo[3,4-d]pyrimidine 2-(4-Hydrazinylpyrazolo[3,4-d]pyrimidin-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol [5-[4-(Benzylamino)pyrazolo[3,4-d]pyrimidin-1-yl]-3,4-dihydroxyoxolan-2-yl]methyl acetate 2-(Hydroxymethyl)-5-(4-prop-2-enylsulfanylpyrazolo[3,4-d]pyrimidin-1-yl)oxolane-3,4-diol N-Benzyl-1-pentofuranosyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 2-(Hydroxymethyl)-5-pyrazolo[3,4-d]pyrimidin-1-yloxolane-3,4-diol [5-[4-(Furan-2-ylmethylamino)pyrazolo[3,4-d]pyrimidin-1-yl]-3,4-dihydroxyoxolan-2-yl]methyl acetate [3,4-Diacetyloxy-5-(4-anilinopyrazolo[3,4-d]pyrimidin-1-yl)oxolan-2-yl]methyl acetate 1-Pentofuranosyl-N-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine [3,4-Diacetyloxy-5-[4-(3-methyl-5-nitroimidazol-4-yl)sulfanylpyrazolo[3,4-d]pyrimidin-1-yl]oxolan-2-yl]methyl acetate 2-[4-(Furan-2-ylmethylamino)pyrazolo[3,4-d]pyrimidin-1-yl]-5-(hydroxymethyl)oxolane-3,4-diol 2-[4-(Hydroxyamino)pyrazolo[3,4-d]pyrimidin-1-yl]-5-(hydroxymethyl)oxolane-3,4-diol 2-(Hydroxymethyl)-5-[4-(3-methyl-5-nitroimidazol-4-yl)sulfanylpyrazolo[3,4-d]pyrimidin-1-yl]oxolane-3,4-diol [3,4-Diacetyloxy-5-[4-(aziridin-1-yl)pyrazolo[3,4-d]pyrimidin-1-yl]oxolan-2-yl]methyl acetate 1-(β-D-ribofuranosyl)-4,6-bis(chlorodifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine 1-(β-D-ribofuranosyl)-4,6-bis(difluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine